Generics sponsors targeting Novartis’s Gilenya (fingolimod) blockbuster treatment for multiple sclerosis have swiftly had a key victory reversed, blocking the potential for imminent US launches of dozens of abbreviated new drug application products.
The US Supreme Court has maintained a longstanding injunction against ANDA sponsors, after agreeing to block the invalidation of a...




